Iterum Therapeutics reported steady initial progress in the commercialization of Orlynda, with early prescriptions showing positive traction among prescribers despite ongoing payer coverage challenges.

• Over 280 prescriptions for Orlynda generated within the early weeks post-launch, with over 100 unique prescribers.
• Around 40% of prescriptions have been filled through specialty pharmacy partners, indicating initial acceptance despite limited payer decisions.
• Collaboration with major distributors McKesson and AmerisourceBergen underway to enhance accessibility for prescribers outside typical purchasing models.
• Positive feedback from physicians highlights Orlynda's potential to treat uncomplicated urinary tract infections effectively, especially in cases of antibiotic resistance.